Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Bladder Urothelial Carcinoma”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03237780
What this trial is testing

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+21 more
National Cancer Institute (NCI) 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT04940299
What this trial is testing

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Bladder Carcinoma+39 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Early research (Phase 1)Active Not RecruitingNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)UnknownNCT00006118
What this trial is testing

Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer

Who this might be right for
Bladder Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
Testing effectiveness (Phase 2)Active Not RecruitingNCT03601455
What this trial is testing

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Who this might be right for
Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8+1 more
Jonsson Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)UnknownNCT04492293
What this trial is testing

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Who this might be right for
Bladder Urothelial Cancer
Beijing InnoCare Pharma Tech Co., Ltd. 115
Early research (Phase 1)Study completedNCT02443324
What this trial is testing

Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more
Eli Lilly and Company 175
Not applicableLooking for participantsNCT06138561
What this trial is testing

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Who this might be right for
Bladder CancerMetastatic Bladder CancerUnresectable Bladder Carcinoma+1 more
Dana-Farber Cancer Institute 180
Testing effectiveness (Phase 2)WithdrawnNCT03935347
What this trial is testing

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma+3 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 132
Testing effectiveness (Phase 2)Study completedNCT00077688
What this trial is testing

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Who this might be right for
Bladder NeoplasmsUreteral NeoplasmsUrethral Neoplasms+1 more
Achieve Life Sciences 44
Early research (Phase 1)Study completedNCT03236935
What this trial is testing

Phase Ib of L-NMMA and Pembrolizumab

Who this might be right for
Non-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell Carcinoma+3 more
The Methodist Hospital Research Institute 12
Testing effectiveness (Phase 2)WithdrawnNCT06424717
What this trial is testing

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Who this might be right for
Urothelial Carcinoma
EMD Serono Research & Development Institute, Inc.
Testing effectiveness (Phase 2)Study completedNCT02178241
What this trial is testing

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Ureter CarcinomaMetastatic Urethral CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7+7 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
ITM Oncologics GmbH 270
Testing effectiveness (Phase 2)Study completedNCT00478361
What this trial is testing

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Who this might be right for
Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral Cancer+8 more
M.D. Anderson Cancer Center 40
Early research (Phase 1)Looking for participantsNCT04878029
What this trial is testing

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+1 more
Emory University 32
Load More Results